Pledpharma AB shares now on First North at NASDAQ OMX Stockholm

Pledpharma AB (short name: PLED) shares will commence today, April 7, on First North at NASDAQ OMX Stockholm. Pledpharma belongs to the Health Care sector.

Pledpharma develops therapies for severe diseases. By streamlining the different treatments the company's drugs are designed to reduce serious side effects while increasing patient survival rates. Pledpharma currently has two projects in clinical Phase II, one in the cancer field and one in the cardiovascular field.

Jenny Rosberg, Senior Vice President at NASDAQ OMX said, "We are pleased that Pledpharma chose to list at First North, one of Europe's most liquid growth markets, where they will make a great addition to our healthcare sector. We continue to see a steady listing inflow to First North and welcome more companies to take advantage of the investor visibility and reach that we can offer."

Pledpharma's CEO, Jacques Näsström, commented, "Today marks an exciting day for our company and we look forward to benefiting from the increased investor exposure at First North. Pledpharma operates in a market with tremendous potential, and on First North we are able to build the capital strength needed to support continued and organic growth."

Pledpharma has appointed Erik Penser Aktiebolag as Certified Advisor.

Read more about PledPharma
Read more about NASDAQ OMX